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tional research and clinical trials. These results contribute to a
better understanding of how QOL issues are perceived by head
and neck patients in India, strengthening the cross-cultural com-
parability of this instrument.
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OBJECTIVES: The objective of this study was to illustrate the
challenges and limitations of using claims data and developing
algorithms to study prescription patterns for metastatic breast
cancer (MBC) in patients previously treated with anthracycline
and taxane. METHODS: Extract from the PharMetrics Inte-
grated Outcomes Database between Janaury 1999 and June
2005 was used. Lacking a diagnosis code for MBC, we deﬁned
the condition = 2 ICD-9 codes for breast cancer (BC) and 1 ICD-
9 code for distant metastases. Drug exposure was deﬁned as °Y´1
NDC/J-code for anthracycline and taxane. A treatment interval
of 21 days was created to account for a high proportion of
missing or zero values for days supply of chemotherapy agents
recorded in claims database and to determine treatment duration
assigned to all agents from reference date, deﬁned as the dispense
date of the ﬁrst anthracycline or taxane prescription, whichever
occurred later. Consecutive intervals with same agents were col-
lapsed into one regimen regardless of sequence; otherwise inter-
vals were treated as separate regimens. RESULTS: Among
38,588 patients with °Y´2 BC diagnoses, 5017 (13%) exhibited
°Y´1 diagnoses for distant metastasis, 1121 (3%) were previously
exposed to an anthracycline and a taxane, and 1028 met other
criteria (age°Y´18 years and eligibility °Y´6 months). Of the 1028,
67% did not receive sequential therapy, and 80% of these had
non-chemotherapy claims 90 days following last chemotherapy,
with a mean post chemotherapy duration of 489 ± 430 days.
Among the 33% who received sequential therapy, the mean
number of sequential therapies was 2.8 ± 2.7 with mean dura-
tion of 66 ± 82 days. CONCLUSION: The current analysis illus-
trates a method of using algorithms to deﬁne MBC diagnoses
and treatment duration in claims-based treatment pattern
studies. However, such algorithms must be validated against the
patients’ medical records in order to assess the respective accu-
racy of disease and treatment pattern identiﬁcation.
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OBJECTIVES: eVOBS is an international, non-interventional,
observational study of clinical and economic outcomes in
patients who receive VELCADE for the approved indication in
multiple myeloma. METHODS: Patients who initiate VELCADE
therapy for the approved indication are eligible for the study.
Retrospective treatment data from 12 months prior to study
entry and prospective treatment data for 36 months are collected
via a secure, privacy-protected website. At study entry, submit-
ted data are electronically screened against validation rules that
have been prospectively established in consultation with multi-
ple myeloma treatment specialists and data analysis specialists.
These rules were designed to prevent missing data, duplicate data
and data outside pre-established, logical ranges. Initial inputs
require study center conﬁrmation before the system uploads data
to the central database. During the study, if there is any data that
is inconsistent with previously submitted entries, study sites
submit corrections via an audited online data change request
system. Finally, an ongoing audit process is used to validate the
quality of the data uploaded to the central database. This process
uses monthly reports to identify potential inconsistencies within
the dataset after data has been validated at entry. RESULTS:
Uploaded data undergoes quality control checks, requiring
adjustment by physicians to be minimal. Audit reports help to
redress data entry training issues, further enhancing data accu-
racy. Analysis is only conducted on patients after resolution of
outstanding supplemental data queries. CONCLUSION: The
goal of this study is document outcomes in a generalizable, rep-
resentative patient cohort. This information will broaden our
understanding of the use of VELCADE in typical clinical prac-
tice, outside of the interventional clinical trial setting. This
largely automated three-stage quality control process streamlines
the implementation of this non-interventional, observational
research and permits the inclusion of patients from a broad geo-
graphic region. The study method allows for faster analysis and
presentation of robust, pragmatic outcomes data.
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OBJECTIVES: To compare the impact of 11 types of cancer on
different domains of HRQL using the FACT-G and EQ-VAS.
METHODS: Patients diagnosed with advanced cancer of the
bladder, brain, breast, colorectal, head/neck, hepatobiliary/pan-
creas, kidney, lung, lymphoma, ovary or prostate completed
HRQL assessments. HRQL was compared between patient
groups for each subscale of the FACT-G, i.e., physical well-being
(PWB), social/family wellbeing (SWB), emotional well-being
(EWB) and functional well-being (FWB), and EQ-VAS, unad-
justed and adjusted for age/gender using regression models.
RESULTS: Approximately 50 patients were recruited for each
cancer group (total n = 534). Mean age (SD) ranged from 52(11)
(brain) to 70(8) (prostate). Unadjusted mean (SD) scores 
for PWB ranged from 66.8(17.2) (head/neck) to 78.1(21.3)
(prostate); for SWB ranged from 81.4(19.1) (brain) to 90.6(22.0)
(kidney); for EWB ranged from 61.7(16.0) (breast) to 72.0(16.9)
(prostate); and FWB ranged from 54.7(20.2) (head/neck) to
67.8(18.5) (prostate). EQ-5D VAS mean scores were lowest for
head/neck [61.8(21.7)] and highest for colorectal [72.0(17.1)].
Compared to lymphoma, adjusting for age/gender, PWB mean
scores (SE) were signiﬁcantly lower for patients with head/neck
[−10.9(4.0)], hepatobiliary [−10.9(4.0)], and kidney [−9.7(4.0)].
FWB mean scores were signiﬁcantly lower for head/neck 
[−10(3.2)], hepatobiliary [−8.9(3.1)], bladder [−7.7(3.6)], and
lung [−6.7(3.1)]. Patients 65 years and older had mean (SE)
scores for PWB = +9.2(2.1), EWB = +2.9(1.0), FWB = +3.1(1.6),
and EQ VAS = +4.5(2.1) compared to patients aged 45 to 64.
For median rank across all FACT subscales, hepatobiliary ranked
worst and prostate the highest. Adjusting for age and gender,
hepatobiliary ranked worst and lymphoma highest based on
FACT median scores, while breast ranked lowest and colorectal
highest based on mean VAS scores. CONCLUSION: Older
